Novavax Inc - Asset Resilience Ratio

Latest as of March 2026: 53.87%

Novavax Inc (NVAX) has an Asset Resilience Ratio of 53.87% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Novavax Inc to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$561.97 Million

Cash + Short-term Investments

Total Assets

$1.04 Billion

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how Novavax Inc's Asset Resilience Ratio has changed over time. See Novavax Inc balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Novavax Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Novavax Inc (NVAX) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$561.97 Million	53.87%
Total Liquid Assets	$561.97 Million	53.87%

Asset Resilience Insights

Very High Liquidity: Novavax Inc maintains exceptional liquid asset reserves at 53.87% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Novavax Inc Industry Peers by Asset Resilience Ratio

Compare Novavax Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Novavax Inc (2006–2025)

The table below shows the annual Asset Resilience Ratio data for Novavax Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	42.03%	$494.45 Million	$1.18 Billion	+16.85pp
2024-12-31	25.18%	$392.89 Million	$1.56 Billion	+24.60pp
2023-12-31	0.58%	$10.42 Million	$1.80 Billion	--
2021-12-31	0.00%	$0.00	$2.58 Billion	--
2020-12-31	9.96%	$157.65 Million	$1.58 Billion	--
2019-12-31	0.00%	$0.00	$172.96 Million	--
2018-12-31	10.57%	$21.98 Million	$207.98 Million	-6.29pp
2017-12-31	16.86%	$51.00 Million	$302.49 Million	-6.25pp
2016-12-31	23.11%	$91.13 Million	$394.30 Million	-12.52pp
2015-12-31	35.63%	$137.55 Million	$386.04 Million	-13.54pp
2014-12-31	49.17%	$135.72 Million	$276.00 Million	+43.41pp
2013-12-31	5.76%	$13.60 Million	$235.94 Million	-20.34pp
2012-12-31	26.10%	$26.71 Million	$102.34 Million	+19.78pp
2011-12-31	6.32%	$4.21 Million	$66.58 Million	-25.24pp
2010-12-31	31.55%	$23.61 Million	$74.84 Million	+26.65pp
2009-12-31	4.90%	$4.19 Million	$85.61 Million	-4.19pp
2008-12-31	9.09%	$6.96 Million	$76.62 Million	-37.07pp
2007-12-31	46.16%	$42.14 Million	$91.29 Million	-8.35pp
2006-12-31	54.51%	$66.43 Million	$121.88 Million	--

pp = percentage points

About Novavax Inc

NASDAQ:NVAX USA Biotechnology

Market Cap

$1.56 Billion

Market Cap Rank

#7215 Global

#2132 in USA

Share Price

$9.50

Change (1 day)

+3.26%

52-Week Range

$6.22 - $11.19

All Time High

$319.93